Gardner Ruth E, Shedlock Katherine E, Fogel Benjamin N
Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Pediatrics. 2025 Apr 1;155(4). doi: 10.1542/peds.2024-066542.
Universal lipid screening is recommended for all pediatric patients aged 9 to 11 years based on 2011 guidelines; however, current screening rates remain low. Our aim was to increase universal lipid screening rates in patients aged 9 to 11 years at our pediatric primary care practices from 5% to 50%.
Baseline screening rates were obtained from May 2019 to April 2021. Provider education and electronic medical record (EMR) clinical decision support (CDS) were introduced in May 2021. Point-of-care (POC) testing was implemented at 1 site in May 2021 and 2 additional sites in May 2022. Provider feedback was performed at 1 site in February 2022, followed by ongoing quarterly provider feedback for all 3 sites in July 2022. Data were collected through April 2023. Rates were plotted on monthly statistical process control charts. Lipid results were analyzed to determine the number of abnormal test results and compared before and after POC testing introduction using χ2 tests.
Baseline testing rates ranged from 1% to 10%, which increased to 18% to 60% at completion of the study period. POC testing and provider feedback were the interventions with the most significant impact, whereas education and EMR CDS alone did not lead to a meaningful increase in screening rates. The proportion of eligible visits with abnormal lipids identified increased from 1.3% to 4.2% after introduction of POC testing.
POC testing and provider feedback are effective strategies to improve universal lipid screening rates and increase the identification of children with abnormal lipids.
根据2011年指南,建议对所有9至11岁的儿科患者进行普遍血脂筛查;然而,目前的筛查率仍然很低。我们的目标是将我们儿科初级保健机构中9至11岁患者的普遍血脂筛查率从5%提高到50%。
2019年5月至2021年4月获得基线筛查率。2021年5月引入了提供者教育和电子病历(EMR)临床决策支持(CDS)。2021年5月在1个地点实施了即时检验(POC),2022年5月在另外2个地点实施。2022年2月在1个地点进行了提供者反馈,随后在2022年7月对所有3个地点进行了持续的季度提供者反馈。数据收集至2023年4月。将筛查率绘制在月度统计过程控制图上。分析血脂结果以确定异常检测结果的数量,并使用χ2检验比较引入POC检测前后的情况。
基线检测率在1%至10%之间,在研究期结束时增至18%至60%。POC检测和提供者反馈是影响最显著的干预措施,而单独的教育和EMR CDS并未导致筛查率有意义的提高。引入POC检测后,确定的血脂异常合格就诊比例从1.3%增至4.2%。
POC检测和提供者反馈是提高普遍血脂筛查率以及增加血脂异常儿童识别率的有效策略。